Literature DB >> 31632187

Wilms tumour in children: 18 years of experience at Vilnius University Hospital Santaros Klinikos, Lithuania.

Milda Rančelytė1, Rolanda Nemanienė2, Lina Ragelienė1, Jelena Rascon1,2.   

Abstract

INTRODUCTION: Wilms tumour (WT) is the most common childhood abdominal malignancy, with an average annual incidence of 1 in 10,000 children. The study published in 2002 reported lower survival rates of WT in Lithuania in comparison to the data of SIOP-9 study and the European Organization for Research and Treatment of Cancer (EORTC). We aimed to assess current diagnostic approach and treatment results of patients with WT treated at our institution and to compare the results with the previously published study.
MATERIALS AND METHODS: A retrospective single-centre study was performed. 48 patients with WT registered at the institutional data-base from 2000 to 2018 were enrolled. An estimated 5-year overall survival (OS5y) and 2-year event-free survival (EFS2y) by stage and risk groups was calculated using IBM SPSS. A comparative analysis of two time periods - 2000-2008 and 2009-2018 - was carried out.
RESULTS: Forty-two (87.5%) patients presented with localised disease and 6 (12.5%) with primary metastatic disease. The majority of cases were of the intermediate-risk group (77%). The OS5yof all analysed children was 86.4%. The EFS2y was 88.9% in stage I, 91.7% in stage II, 83.3% in stage III, and 50% in stage IV. The EFS2y was 100% in the low-risk group, 86.5% in the intermediate-risk group, and 25% in the high-risk group. Improvement of outcomes was observed over the analysed period: OS5y changed from 81.0% in 2000-2008 to 92.6% in 2009-2018. Among 48 cases, ten patients showed recurrence: eight - early relapse and two - late relapse. Six patients died.
CONCLUSIONS: WT was diagnosed at early stages in most cases. The  survival was better among the  patients diagnosed in earlier stages and with favourable risk group. Better survival rates were observed in patients treated in 2009-2018 compared to the 2000-2008 period. © Lietuvos mokslų akademija, 2019.

Entities:  

Keywords:  SIOP; Wilms tumour; children; survival

Year:  2019        PMID: 31632187      PMCID: PMC6779473          DOI: 10.6001/actamedica.v26i2.4033

Source DB:  PubMed          Journal:  Acta Med Litu        ISSN: 1392-0138


  16 in total

Review 1.  Wilms' tumor in children: an overview.

Authors:  Ali Varan
Journal:  Nephron Clin Pract       Date:  2008

Review 2.  Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Marry M van den Heuvel-Eibrink; Janna A Hol; Kathy Pritchard-Jones; Harm van Tinteren; Rhoikos Furtwängler; Arnauld C Verschuur; Gordan M Vujanic; Ivo Leuschner; Jesper Brok; Christian Rübe; Anne M Smets; Geert O Janssens; Jan Godzinski; Gema L Ramírez-Villar; Beatriz de Camargo; Heidi Segers; Paola Collini; Manfred Gessler; Christophe Bergeron; Filippo Spreafico; Norbert Graf
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

3.  Wilms' tumor--lessons and outcomes--a 25-year single center UK experience.

Authors:  David W Fawkner-Corbett; Lisa Howell; Barry L Pizer; Carlo Dominici; Heather P McDowell; Paul D Losty
Journal:  Pediatr Hematol Oncol       Date:  2014-06-16       Impact factor: 1.969

4.  Survival of children with Wilms' tumour in Europe.

Authors:  I Plesko; E Kramárová; C A Stiller; J W Coebergh; M Santaquilani
Journal:  Eur J Cancer       Date:  2001-04       Impact factor: 9.162

5.  Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.

Authors:  Igne Kairiene; Ramune Pasauliene; Nadezda Lipunova; Goda Vaitkeviciene; Lina Rageliene; Jelena Rascon
Journal:  Eur J Pediatr       Date:  2017-08-15       Impact factor: 3.183

6.  Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

Authors:  Kathy Pritchard-Jones; Christophe Bergeron; Beatriz de Camargo; Marry M van den Heuvel-Eibrink; Tomas Acha; Jan Godzinski; Foppe Oldenburger; Liliane Boccon-Gibod; Ivo Leuschner; Gordan Vujanic; Bengt Sandstedt; Jan de Kraker; Harm van Tinteren; Norbert Graf
Journal:  Lancet       Date:  2015-07-09       Impact factor: 79.321

Review 7.  Epidemiology of Wilms tumor.

Authors:  N Breslow; A Olshan; J B Beckwith; D M Green
Journal:  Med Pediatr Oncol       Date:  1993

8.  Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America.

Authors:  Dimitrios Doganis; Paraskevi Panagopoulou; Athanasios Tragiannidis; Theodoros Vichos; Maria Moschovi; Sofia Polychronopoulou; Efthimia Rigatou; Eugenia Papakonstantinou; Eftichia Stiakaki; Helen Dana; Panagiota Bouka; Luis Antunes; Joana Bastos; Daniela Coza; Anna Demetriou; Domenic Agius; Sultan Eser; Anton Ryzhov; Mario Sekerija; Maciej Trojanowski; Tina Zagar; Anna Zborovskaya; Snezana Zivkovic Perisic; Katerina Strantzia; Nick Dessypris; Theodora Psaltopoulou; Eleni Th Petridou
Journal:  Eur J Cancer       Date:  2018-07-17       Impact factor: 9.162

9.  Malformations, genetic abnormalities, and Wilms tumor.

Authors:  S Dumoucel; M Gauthier-Villars; D Stoppa-Lyonnet; P Parisot; H Brisse; P Philippe-Chomette; S Sarnacki; L Boccon-Gibod; S Rossignol; C Baumann; I Aerts; F Bourdeaut; F Doz; D Orbach; H Pacquement; J Michon; G Schleiermacher
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

10.  Results of neuroblastoma treatment in Lithuania: a single centre experience.

Authors:  Austėja Juškaitė; Indrė Tamulienė; Jelena Rascon
Journal:  Acta Med Litu       Date:  2017
View more
  2 in total

1.  Improvement in childhood cancer survival in Lithuania over three decades.

Authors:  Jelena Rascon; Giedrė Smailytė
Journal:  Acta Med Litu       Date:  2020

2.  The impact of incomplete registration on survival rate of children with very rare tumors.

Authors:  Jelena Rascon; Lukas Salasevicius; Giedre Rutkauskiene; Ewa Bien; Ieva Vincerzevskiene
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.